RTV
vs IND
RTV vs
IND Efficacy
A
randomized trial comparing the introduction of ritonavir or indinavir in 1251
nucleoside-experienced patients with advanced HIV infection.
ISS-IP1 Clinical Investigators. Floridia M,
Tomino C, Bucciardini R, et al.
AIDS Res
Hum Retroviruses 2000 Nov
20;16(17):1809-20
Abstract
RTV/IND
Efficacy
| |
Efficacy of a twice-daily antiretroviral regimen containing 100 mg
ritonavir/400 mg indinavir in HIV-infected patients.
Ghosn J, Lamotte C, Ait-Mohand H, et al.
AIDS 2003 Jan 24;17(2):209-14
Abstract
|
|
| |
|
|
| |
Dose-finding
study of a once-daily indinavir/ritonavir regimen.
Hugen PW, Burger DM, ter Hofstede HJ, et al.
J Acquir Immune Defic
Syndr 2000 Nov 1;25(3):236-45
Abstract
|
|
| |
|
|
| |
Dose-finding
study of a once-daily indinavir/ritonavir regimen.
Hugen PW, Burger DM, ter Hofstede HJ, et al.
J Acquir Immune Defic
Syndr 2000 Nov 1;25(3):236-45
Abstract
|
|
| |
|
|
| |
Enhanced
penetration of indinavir in cerebrospinal fluid and semen after the addition
of
low-dose ritonavir.
van Praag RM, Weverling GJ,
Portegies P, et al.
AIDS
2000 Jun
16;14(9):1187-94
Abstract |
|
RTV/IND/Double Nucleosides
Efficacy and Safety
Efficacy
and safety of twice daily first-line ritonavir/indinavir plus double
nucleoside
combination therapy in
HIV-infected individuals.
German
Ritonavir/Indinavir Study Group. Rockstroh JK, Bergmann F, Wiesel W, et al.
AIDS
2000 Jun 16;14(9):1181-5
Abstract
RTV/IND/DVD/NRTIs
Switching Therapy
RTV/IND/ZDV/3TC
Dose Finding Study
Dose-finding
study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in
HIV-infected patients.
Mallolas J, Blanco
JL, Sarasa M, et al..
J
Acquir Immune Defic Syndr 2000 Nov
1;25(3):229-35
Abstract
RTV NFV
Safety/Tolerability
Safety,
tolerability, and antiretroviral effects of ritonavir-nelfinavir combination
therapy
administered for 48 weeks.
Raines
CP, Flexner C, Sun E, et al.
J
Acquir Immune Defic Syndr
2000
Dec 1;25(4):322-8
Abstract
RTV
vs NFV
vs EFV + one
protease inhibitor
Comparison of initial combination antiretroviral therapy with a single
protease inhibitor,
ritonavir and saquinavir,or efavirenz.
Lucas GM,
Chaisson RE, Moore RD.
AIDS
2001 Sep 7;15(13):1679-1686
Abstract
RTV/SQV
Drug Interactions
RTV/SQV/fusidic acid
A
drug interaction between fusidic acid and a combination of ritonavir and
saquinavir.
Khaliq Y, Gallicano K, Leger R, Foster B,
et al.
Br J Clin
Pharmacol 2000 Jul;50(1):82-3
Abstract
RTV/SQV/sildenafil
Pharmacokinetic
interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N
Br J Clin Pharmacol 2000
Aug;50(2):99-107
Abstract
Viral
Dynamics/Response
Cerebrospinal
fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S, Gallicano K, Roth V, et al.
Acquir Immune Defic Syndr 1999 Aug
15;21(5):371-5
Abstract
Efficacy
| |
FULL-TEXT
ARTICLE
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in
human
immunodeficiency
virus-infected
patients.
Michelet C, Ruffault A, Sebille V, et al.
Antimicrob Agents Chemother 2001 Dec;45(12):3393-402
Paper |
| |
|
| |
FULL-TEXT ARTICLE
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in
human
immunodeficiency
virus-infected patients.
Michelet C, Ruffault A, Sebille V, et al.
Antimicrob Agents Chemother 2001 Dec;45(12):3393-402
Paper |
| |
|
| |
Safety
and Efficacy of Reduced Doses of Ritonavir (RTV) Plus Saquinavir (SQV) in the
Treatment of AIDS Patients in Brazil.
Brites C, Alcantara AP, Mosqueira B, et al.
Braz
J Infect Dis 1999 Jun;3(3):91-96
Abstract |
| |
|
| |
Ritonavir
and saquinavir combination therapy for the treatment of HIV infection.
Cameron DW, Japour AJ, Xu Y, et al.
AIDS
1999 Feb 4;13(2):213-24
Abstract
|
Resistance
HIV-1
genotypic resistance patterns predict response to saquinavir-ritonavir
therapy in patients in whom previous inhibitor therapy had failed.
Zolopa AR, Shafer RW, Warford A, et al.
Ann Intern Med 1999
Dec 7;131(11):813-21
Abstract
Adverse Events
Hepatitis/Hepatotoxicity
Risk
Factors for Hepatotoxicity in HIV-1-Infected Patients Receiving Ritonavir and
Saquinavir with or without Stavudine.
Gisolf EH, Dreezen C, Danner SA,
et al.
Clin
Infect Dis 2000 Nov;31(5):1234-1239
Abstract
Clinical Management Strategies
First-Line Therapy
Efficacy
and safety of twice daily first-line ritonavir/indinavir plus double
nucleoside combination therapy in HIV-infected individuals. German
Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, et al.
AIDS
2000 Jun 16;14(9):1181-5
Abstract
Intensification Therapy
The
effect of treatment intensification in HIV-infection: a study comparing
treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine.
Prometheus Study Group. Gisolf EH, Jurriaans S, Pelgrom J, et al.
AIDS
2000 Mar 10;14(4):405-13
Abstract
Salvage Therapy
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir
therapy in
patients in whom previous protease inhibitor therapy had failed.
Zolopa AR, Shafer RW, Warford A, et
al.
Ann Intern Med 1999 Dec 7;131(11):813-21
Abstract
Quality of Life
Quality
of life in asymptomatic- and symptomatic HIV infected patients in a trial of
ritonavir/saquinavir therapy.
The Prometheus Study
Group. Nieuwkerk PT, Gisolf EH,
Colebunders R, et al.
AIDS 2000 Jan
28;14(2):181-7
Abstract
RTV/SQV vs
RTV
FULL-TEXT
ARTICLE
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in
human
immunodeficiency virus-infected patients.
Michelet C,
Ruffault A, Sebille V, et al.
Antimicrob Agents Chemother 2001Dec;45(12):3393-402
Paper
RTV/SQV vs RTV/SQV/D4T
Efficacy
The
effect of treatment intensification in HIV-infection: a study comparing
treatment
with ritonavir/and ritonavir/saquinavir/stavudine.
Prometheus Study Group. Gisolf EH, Jurriaans S, Pelgrom J, et al.
AIDS
2000 Mar 10;14(4):405-13
Abstract
Efficacy
Assessing
efficacy by measuring CD(4) counts and quality of life of AIDS patients
treated with ritonavir, AZT and 3TC.
de Andrade JL Neto, Focaccia Siciliano R
Braz J
Infect Dis 2000 Aug;4(4):173-82
Abstract
Resistance
Effect
of zidovudine resistance mutations on virologic response to treatment with
zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency
virus type 1 isolates from AIDS clinical trials group protocol 315.
ACTG Protocol 315 Team. Kuritzkes DR, Sevin A, Young B,
et al.
J
Infect Dis
2000 Feb;181(2):491-7
Abstract
Clinical Management Strategies
Assessing
efficacy by measuring CD(4) counts and quality of life of AIDS patients
treated with ritonavir, AZT and 3TC.
de Andrade JL Neto, Focaccia Siciliano R
Braz J
Infect Dis 2000 Aug;4(4):173-82
Abstract
HIV/HCV Coinfection
Kaposi’s Sarcoma
|
Guidelines
Ritonavir
Main Page
Documents identified with this icon are in Portable Document
Format (PDF) and
require the
Adobe Acrobat Reader 5 and may take a few minutes to
download.